TGFB1 and non-small cell lung carcinoma: CAFs promotes EMT and resistance to cisplatin in non-small cell lung cancer (NSCLC) via the TGF-β/IL-6 axis; cisplatin treatment also increases the secretion of TGF-β in cancer cells, leading to CAFs activation and increased IL-6 secretion (Shintani et al., 2016).